ClinicalTrials.gg
Enrolling by invitationNCT06158490Updated Mar 20, 2025

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

A Phase 2 interventional study of JYP0061 15 mg and JYP0061 30 mg in Moderate-to-severe Atopic Dermatitis, sponsored by Guangzhou JOYO Pharma Co., Ltd. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Guangzhou JOYO Pharma Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
116th of 190
120 · median 164
Started
2023
with 38 others
Phase 2
58 of 206
16 open now
Primary completion
2026-02
later than 20 of 81 live
Registered
94th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 116th largest by planned enrollment of the 190 interventional ones that give a count, is one of 39 that started in 2023, is one of 58 in phase 2, reaches primary completion later than 20 of the 81 other live ones, and was the 94th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are:

  • The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis.
  • The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis.

Participants will:

  • Be treated with either a low-dose or high-dose of JYP0061.
  • Undergo efficacy and safety evaluations as stipulated in the trial protocol.
Read the detailed description

The goal of this clinical trial is to assess JYP0061 for efficacy and safety in adult patients with moderate-to-severe atopic dermatitis. The main objectives it aims to address are the determination of the drug's therapeutic effect and its safety profile in this patient population. Upon providing written informed consent after being briefed on the study details and potential risks, participants will enter a screening period of up to 4 weeks to confirm their eligibility.

The main tasks for participants will include:

  • Being randomized to receive either a low-dose or high-dose of JYP0061.
  • Completing a treatment course of 12 weeks.
  • Undergoing efficacy and safety assessments as prescribed by the study's protocol.

Following the treatment phase, all participants, whether they have completed the treatment course on schedule or have discontinued early, will be monitored for an additional 4 weeks to further evaluate safety post-treatment.

03

Conditions studied

  • Moderate-to-severe Atopic Dermatitis

Browse trials for

Keywords

  • atopic dermatitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The age of the participants should be between 18 and 65 years old, with no restrictions on gender.
  • Participants must weigh 40 kg or more
  • At the time of screening, participants must meet the Williams criteria for atopic dermatitis, have had the condition for at least one year, and the severity of the disease should be moderate to severe;
  • Participants agree from the time of signing the form until the completion of the study's final visit to use only non-medicated emollients (moisturizing creams) or other concomitant treatments allowed by the protocol.
  • Fully understand the purpose and requirements of this trial, voluntarily participate, and sign the written informed consent form, and are able to complete the study according to its requirements.

Exclusion criteria

Exclusion Criteria:

  • Suspected or confirmed allergy to any component of the study drug or similar ingredients, or having a history of moderate allergic diseases (such as food allergies, drug allergies, etc., except for allergies related to atopic dermatitis) at the time of signing the form;
  • At the time of screening, having other skin diseases or skin infections that could affect the evaluation of the trial results, or having extensive tattoos, birthmarks, skin scars, etc., in the area of skin lesions, aside from atopic dermatitis;
  • Having or having had other connective tissue diseases, apart from a history of atopic dermatitis;
  • Participation in another clinical trial within one month prior to screening or within five half-lives of the drug (whichever is longer);
  • Underwent major surgery within 12 weeks prior to screening;
  • Conditions that negatively affect the immune response (such as history of organ transplantation), or subjects with known immunodeficiency syndromes (acquired immunodeficiency syndrome, genetic immunodeficiency, and drug-induced immunodeficiency).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    JYP0061 15 mg Group

    Participants in this arm will receive 15 mg of JYP0061 once daily for a total treatment period of 12 weeks.

    Drug: JYP0061 15 mg

  • Experimental
    JYP0061 30 mg Group

    articipants in this arm will receive 30 mg of JYP0061 once daily for a total treatment period of 12 weeks.

    Drug: JYP0061 30 mg

  • Placebo comparator
    Placebo Group

    Participants in this arm will receive a placebo once daily for a total treatment period of 12 weeks.

    Drug: Placebo

Interventions

  • Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.

  • articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.

  • DrugPlacebo

    Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) from baseline.

    The Eczema Area and Severity Index (EASI) is a measure of eczema severity, combining area coverage and symptom intensity (erythema, edema/papulation, excoriation, lichenification) for four body regions. EASI scores range from 0 (no eczema) to 72 (maximum severity), with higher scores indicating worse outcomes. This primary outcome assesses the proportion of participants who achieve at least a 75% reduction in EASI from baseline to Week 12.

    Time frame: Evaluations will be conducted weekly for up to 12 weeks

Secondary outcomes

  1. Proportion of participants achieving EASI 75 at Weeks 2, 4, and 8.

    Percentage of participants achieving a 75% reduction in EASI from baseline at each specified week.

    Time frame: Weeks 2, 4, and 8.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Feb 2026, 25 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 25 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2023
First posted
Dec 6, 2023
StartActual
Dec 27, 2023
Primary completionEst.
Feb 10, 2026
CompletionEst.
Oct 10, 2026
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06158490
Lead sponsor
Guangzhou JOYO Pharma Co., Ltd
Responsible party
Sponsor
First posted
Dec 6, 2023
Start date
Dec 27, 2023
Primary completion
Feb 10, 2026 (estimated)
Completion
Oct 10, 2026 (estimated)
Last update
Mar 20, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JYP0061

Start the discussion